gnbt - momento da verdade
according to :
asco 2010 ABSTRACT....
we know that using AE37 in BC patients would give recurrence rate of 2.9% (2 out of 67) and without using AE37 recurrence rate is 7.2% (6 out 83)
the questions that we ask ourselves are:
1- What can we learn from these numbers?
2- What should we expect to get from PIII
3- Does AE37 work?
The Answers are:
1- We can learn alot from the above:
when we use a group of 67 patients and we
estimate the probability of recurrence which is 0.029, we know from the probbaility and statistic theory (see fro example Probability & statistic by A. Papoulis p.283) that the standard diviation of this kind of estimation is d=sqrt(p*(1-p)/N) where , and we also know that using the +/- sigma theory we can expect that for future trials 68% of the results would give p-d=0.029 or p+d=0.029
solving the above would give the following:
p=1/67 -- 4/67 or 1.5% to 5.9%
this means that on the worse case we would have 5.9% recurence this is still better than 7.2% by about 18.1%, however we can also get the best result which is 1.5% which is 79.2% better comapred to non AE37 case, BUT we should expect to get sometyhing in the middle which is recurrence=3.7% (1.5+5.9)/2 which is about 48.6% better to non AE37.
when we have compared to the non AE37 case we used recurrence as we saw on the Generex ASCO
abstract which was 7.2%. this number could be verified with the surce : http://www.gaeainitiative.eu/word_page/B... which indicates that recurrence after about 13-14mo is about 7.2%.
2. base on the above we can say that we should expect a 3.7% recurrence using AE37 compared to 7.2% without using the AE37 which is abot 48% better
3. Using the results so far and the probability & statistic theory (Papoulis p. 283) we have concluded that on the worse case the recurrence would be 5.9% and the best would be 1.5% but both are unlikley so we can expect with high probability to get something in the middle which is 3.7% so the answer YES AE37 WORKS!!!!!
==> 48.6% better to non AE37
asco 2010 ABSTRACT....
we know that using AE37 in BC patients would give recurrence rate of 2.9% (2 out of 67) and without using AE37 recurrence rate is 7.2% (6 out 83)
the questions that we ask ourselves are:
1- What can we learn from these numbers?
2- What should we expect to get from PIII
3- Does AE37 work?
The Answers are:
1- We can learn alot from the above:
when we use a group of 67 patients and we
estimate the probability of recurrence which is 0.029, we know from the probbaility and statistic theory (see fro example Probability & statistic by A. Papoulis p.283) that the standard diviation of this kind of estimation is d=sqrt(p*(1-p)/N) where , and we also know that using the +/- sigma theory we can expect that for future trials 68% of the results would give p-d=0.029 or p+d=0.029
solving the above would give the following:
p=1/67 -- 4/67 or 1.5% to 5.9%
this means that on the worse case we would have 5.9% recurence this is still better than 7.2% by about 18.1%, however we can also get the best result which is 1.5% which is 79.2% better comapred to non AE37 case, BUT we should expect to get sometyhing in the middle which is recurrence=3.7% (1.5+5.9)/2 which is about 48.6% better to non AE37.
when we have compared to the non AE37 case we used recurrence as we saw on the Generex ASCO
abstract which was 7.2%. this number could be verified with the surce : http://www.gaeainitiative.eu/word_page/B... which indicates that recurrence after about 13-14mo is about 7.2%.
2. base on the above we can say that we should expect a 3.7% recurrence using AE37 compared to 7.2% without using the AE37 which is abot 48% better
3. Using the results so far and the probability & statistic theory (Papoulis p. 283) we have concluded that on the worse case the recurrence would be 5.9% and the best would be 1.5% but both are unlikley so we can expect with high probability to get something in the middle which is 3.7% so the answer YES AE37 WORKS!!!!!
==> 48.6% better to non AE37
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
32nd Annual Gary P. Wratten Symposium
A generex participou no dia 27 de Maio de 2010 nesta conferência:
32nd Annual Gary P. Wratten Symposium
https://www01.hjf.org/apps/internet/eve ... ram.2x.pdf
reparem no orador.... e no tema .....
a gnbt não divulgou nenhuma press release com isto....
será normal? estranho.....
Cumprimentos
32nd Annual Gary P. Wratten Symposium
https://www01.hjf.org/apps/internet/eve ... ram.2x.pdf
reparem no orador.... e no tema .....
a gnbt não divulgou nenhuma press release com isto....
será normal? estranho.....
Cumprimentos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Resultados trimestrais
Parece que é hoje que a generex apresenta os resultados trimestrais...
http://biz.yahoo.com/research/earncal/today.html
confesso que pensava que seria ontem..... estranho....
estranho também aquilo que se passou ontem na ASCO 2010....
http://biz.yahoo.com/research/earncal/today.html
confesso que pensava que seria ontem..... estranho....
estranho também aquilo que se passou ontem na ASCO 2010....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Shevet Escreveu:Isto da ASCO parece que não vai dar em nada..........looool
Pedrinni tens alguma noticia de hoje???
A GNBT tem suporte a 0,37usd mas não está a querer aguentartb não consigo perceber se estão a dar papel ou a ir buscar
Abraço
Shevet
A gnbt anunciou a apresentação de nova informação sobre o AE37 para a ASCO 2010:
New data from Antigen Express' lead immunotherapeutic AE37, a synthetic peptide vaccine designed to prevent the recurrence of a variety of different cancers that express the HER-2/neu protein, will be shared in a presentation by Guy Clifton of the abstract "Effect of a Novel Ii-Key Hybrid HER2/neu Peptide AE37 Vaccine with GM-CSF as Compared to GM-CSF Alone on Levels of Regulatory T-cell Treg Populations."
"New Data"
Onde está ela? Boa pergunta
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Isto da ASCO parece que não vai dar em nada..........looool
Pedrinni tens alguma noticia de hoje???
A GNBT tem suporte a 0,37usd mas não está a querer aguentar tb não consigo perceber se estão a dar papel ou a ir buscar
Abraço
Shevet
Pedrinni tens alguma noticia de hoje???
A GNBT tem suporte a 0,37usd mas não está a querer aguentar
tb não consigo perceber se estão a dar papel ou a ir buscar
Abraço
Shevet
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
AC Investor Blog Escreveu:pedro200 Escreveu:... Rumores de possível takeover nos blogs...
será?
úma coisa é certa! é a altura ideal, antes que a gnbt levante voo...
Pedro, fiz uma análise técnica á GNBT no blog, não sei se vistes. Apartir dos 0.45 é sempre a subir. Não costumo investir muito em penny stocks , mas esta como está na lista das possiveis DNDN, tive que lá meter uns trocos
Sem sombra de dúvida!!
0,45 parece ser o número mágico para esta!
- Anexos
-
- GNBT.jpg (63.6 KiB) Visualizado 6781 vezes
- Mensagens: 81
- Registado: 27/3/2009 23:12
- Localização: 15
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
pasil74 Escreveu:Boas
Já reforcei com mais algumas, mas não há maneira de descolar
vamos esperar pela press release relativa aos resultados do AE37 - fase II beast cancer. Se não sair hoje deve sair amanhã. Uma coisa é certa. Estão a conseguir segurar a gnbt.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Ora aqui vai uma fresquinha...........
WORCESTER, Mass., Jun 7, 2010 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today reported preliminary outcomes and trends from the ongoing Phase III pivotal study of Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product.
Observations were made regarding insulin antibody levels, weight gain, body mass index, and hypoglycemic events. Information on reported trends has been collected from in-process, non-finalized data. With over 400 subjects now enrolled in the Phase III global clinical trial of Generex Oral-lyn(TM), a brief look at open data from the Electronic Data Capturing System (EDC) reveals the following for subjects that completed the 6-month treatment phase of the study:
Insulin resistance has not been observed for subjects using Generex Oral-lyn(TM). Subjects using Generex Oral-lyn(TM) demonstrated no weight gain, on average, and an actual decrease in Body Mass Index (BMI). This compares favorably to subjects using injectable insulin that have, on average, gained weight and experienced an increase in BMI. When comparing hypoglycemic events, subjects using Generex Oral-lyn(TM) were observed to have a better Adverse Event profit than subjects using injectable insulin. Furthermore, there have been fewer severe hypoglycemic events for those using Generex Oral-lyn(TM) than those using injectable insulin.
"We are very pleased that these key characteristics often monitored throughout insulin treatments are trending favorably," stated Anna Gluskin, Generex's President & Chief Executive Officer. "As weight gain and hypoglycemic events are often negative side effects of injectable insulin, it is extremely encouraging that regular administration of Generex Oral-lyn(TM) has been observed to result in a decrease in BMI and fewer severe hypoglycemic events."
These reported trends and outcomes are preliminary only. Once approximately 450 subjects are enrolled in the study, a formal interim analysis of the collected data is planned.
While the Phase III global study continues, Generex Oral-lyn(TM) remains available under the Treatment IND program in the United States. In September 2009, the FDA granted approval to Generex to proceed with the treatment use of Generex Oral-lyn(TM) under the Treatment IND program, pursuant to which the product can be provided to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for the treatment of diabetes, and who are not eligible to participate in the Company's Phase III study of the product. The Treatment IND program is open to eligible patients in the USA who comply with the selection criteria of the treatment protocol, including those who are taking currently approved anti-diabetic medications. There are no oral or injectable medications contraindicated for the program.
To learn more about the availability of Generex Oral-lyn(TM) under the Treatment IND program, the Company has provided information within the www.ClinicalTrials.gov website on the program design and contact information on all participating sites and/or physicians.
Abraço
Shevet
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 78
- Registado: 3/5/2010 21:32
- Localização: 10
Recordo a entrevista da ceo da generex em Fevereiro:
http://www.youtube.com/watch?v=W0nkrO5vnc4
reparem no minuto 4:18
os primeiros 6 meses do ano estão a acabar...
se o que ela afirma for verdade....
aguardemos
http://www.youtube.com/watch?v=W0nkrO5vnc4
reparem no minuto 4:18
os primeiros 6 meses do ano estão a acabar...
se o que ela afirma for verdade....
aguardemos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Quem está ligado:
Utilizadores a ver este Fórum: Bing [Bot], Google Feedfetcher, latbal, nickforum, OCTAMA, PAULOJOAO, peterteam2 e 149 visitantes